Aberrant Promoter Methylation of YAP Gene and its Subsequent Downregulation in Indian Breast Cancer Patients

BMC Cancer

Table 7 Correlation analysis of methylation and protein expression in samples having methylated YAP1 promoter or YAP1 expression loss with the clinical parameters in Indian breast cancer patients

Characteristic	Total (N)	Methylated YAP1		p value	Total (N)	YAP1 loss		p value
Characteristic	Total (N)	YAP1 Absent	YAP1 Present	p value	Total (N)	Unmethylated YAP1	Methylated YAP1	p value
Age (years)
≤50	57	50	7	0.767	64	14	50	1
>50	40	34	6		44	10	34
Age at menarche
≤12	18	17	1	0.451	23	6	17	0.585
>12	79	67	12		85	18	67
Menopausal status
Premenopausal	28	23	5	0.512	32	9	23	0.447
Postmenopausal	69	61	8		76	15	61
Age at menopause
≤45	21	21	0	0.095	28	7	21	0.388
>45	48	40	8		48	8	40
ER status
Positive	54	45	9	0.375	58	13	45	1
Negative	43	39	4		50	11	39
PR status
Positive	35	30	5	1	38	8	30	1
Negative	62	54	8		70	16	54
Her2 status
Positive	48	42	6	1	52	10	42	0.497
Negative	49	42	7		56	14	42
Molecular subtypes of breast cancer
Luminal A	30	25	5	0.837	33	8	25	0.87
Luminal B	26	22	4		28	6	22
Her2-enriched	22	20	2		24	4	20
TNBC	19	17	2		23	6	17
Tumor size
≤5	40	36	4	0.549	47	11	36	0.819
>5	57	48	9		61	13	48
Lymph node status
Positive	70	61	9	0.751	77	16	61	0.613
Negative	27	23	4		31	8	23
Clinical stage
I+II	34	31	3	0.533	38	7	31	0.629
III+IV	63	53	10		70	17	53
Histological grade
I+II	68	59	9	1	76	17	59	1
III	29	25	4		32	7	25

ISSN: 1471-2407